Trial · NCT01202409
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
NCT01202409, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2020-02-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater. Trials, record NCT01202409. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01202409
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
- NCT number
- NCT01202409
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 19 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Gastrointestinal Cancer
- Interventions
- Panitumumab
- First posted
- 2010-09-15
- Last updated
- 2020-02-21
- Results first posted
- 2020-02-21
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate (RR) | up to 100 weeks | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Secondary | Overall Progression-free Survival (PFS) for CAPOX and Panitumumab | 7.6 months | Time interval in months from date of first treatment until the date of first documented progression of participants. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate (RR) | up to 100 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Progression-free Survival (PFS) for CAPOX and Panitumumab | 7.6 months | months | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate (RR) | Capecitabine + Panitumumab + Oxaliplatin | 19 | Participants | ||
| Overall Progression-free Survival (PFS) for CAPOX and Panitumumab | Capecitabine + Panitumumab + Oxaliplatin | 2.4 | Full Range 1 to 7.6 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Capecitabine + Panitumumab + Oxaliplatin | 19 | |
| Overall Study | COMPLETED | Capecitabine + Panitumumab + Oxaliplatin | 11 | |
| Overall Study | NOT COMPLETED | Capecitabine + Panitumumab + Oxaliplatin | 8 |
Source ClinicalTrials.gov
Adverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Capecitabine + Panitumumab + Oxaliplatin | 2 | 19 | |
| other | Alanine Aminotransferase increased | Investigations | Capecitabine + Panitumumab + Oxaliplatin | 2 | 19 | |
| other | Alkaline phosphatase increased | Investigations | Capecitabine + Panitumumab + Oxaliplatin | 3 | 19 | |
| other | Anemia | Blood and lymphatic system disorders | Capecitabine + Panitumumab + Oxaliplatin | 4 | 19 | |
| other | Anorexia | Metabolism and nutrition disorders | Capecitabine + Panitumumab + Oxaliplatin | 4 | 19 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Capecitabine + Panitumumab + Oxaliplatin | 1 | 19 | |
| other | Aspartate aminotransferase increased | Investigations | Capecitabine + Panitumumab + Oxaliplatin | 2 | 19 | |
| other | Constipation | Gastrointestinal disorders | Capecitabine + Panitumumab + Oxaliplatin | 1 | 19 | |
| other | Dehydration | Metabolism and nutrition disorders | Capecitabine + Panitumumab + Oxaliplatin | 2 | 19 | |
| other | Diarrhea | Gastrointestinal disorders | Capecitabine + Panitumumab + Oxaliplatin | 2 | 19 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Capecitabine + Panitumumab + Oxaliplatin | 19 | 19 |
| Total, other adverse events | Capecitabine + Panitumumab + Oxaliplatin | 19 | 19 |
| Total, serious adverse events | Capecitabine + Panitumumab + Oxaliplatin | 2 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29259073 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01202409
GET https://conductscience.org/api/trials/v1/NCT01202409/events?page=2